PT  - JOURNAL ARTICLE
AU  - de Rojas, Itziar
AU  - Moreno-Grau, Sonia
AU  - Tesi, Niccolò
AU  - Grenier-Boley, Benjamin
AU  - Andrade, Victor
AU  - Jansen, Iris
AU  - Pedersen, Nancy L.
AU  - Stringa, Najada
AU  - Zettergren, Anna
AU  - Hernández, Isabel
AU  - Montrreal, Laura
AU  - Antúnez, Carmen
AU  - Antonell, Anna
AU  - Tankard, Rick M.
AU  - Bis, Joshua C.
AU  - Sims, Rebecca
AU  - Bellenguez, Céline
AU  - Quintela, Inés
AU  - González-Perez, Antonio
AU  - Calero, Miguel
AU  - Franco, Emilio
AU  - Macías, Juan
AU  - Blesa, Rafael
AU  - Menéndez-González, Manuel
AU  - Frank-García, Ana
AU  - Luís Royo, Jose
AU  - Moreno, Fermín
AU  - Huerto, Raquel
AU  - Baquero, Miquel
AU  - Diez-Fairen, Mónica
AU  - Lage, Carmen
AU  - Garcia-Madrona, Sebastian
AU  - García, Pablo
AU  - Alarcón-Martín, Emilio
AU  - Valero, Sergi
AU  - Sotolongo-Grau, Oscar
AU - EADB, GR@ACE, DEGESCO, IGAP (ADGC, CHARGE, EADI, GERAD) and PGC-ALZ Consortia
AU  - Garcia-Ribas, Guillermo
AU  - Sánchez-Juan, Pascual
AU  - Pastor, Pau
AU  - Pérez-Tur, Jordi
AU  - Piñol-Ripoll, Gerard
AU  - de Munain, Adolfo Lopez
AU  - García-Alberca, Jose María
AU  - Bullido, María J.
AU  - Álvarez, Victoria
AU  - Lleó, Alberto
AU  - Real, Luis M.
AU  - Mir, Pablo
AU  - Medina, Miguel
AU  - Scheltens, Philip
AU  - Holstege, Henne
AU  - Marquié, Marta
AU  - Sáez, María Eugenia
AU  - Carracedo, Ángel
AU  - Amouyel, Philippe
AU  - Williams, Julie
AU  - Seshadri, Sudha
AU  - van Duijn, Cornelia M.
AU  - Mather, Karen A.
AU  - Sánchez-Valle, Raquel
AU  - Serrano-Ríos, Manuel
AU  - Orellana, Adelina
AU  - Tárraga, Lluís
AU  - Blennow, Kaj
AU  - Huisman, Martijn
AU  - Andreassen, Ole A.
AU  - Posthuma, Danielle
AU  - Clarimón, Jordi
AU  - Boada, Mercè
AU  - van der Flier, Wiesje M.
AU  - Ramirez, Alfredo
AU  - Lambert, Jean-Charles
AU  - van der Lee, Sven J.
AU  - Ruiz, Agustín
TI  - Common variants in Alzheimer’s disease: Novel association of six genetic variants with AD and risk stratification by polygenic risk scores
AID  - 10.1101/19012021
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 19012021
4099  - http://medrxiv.org/content/early/2020/01/17/19012021.short
4100  - http://medrxiv.org/content/early/2020/01/17/19012021.full
AB  - BACKGROUND Disentangling the genetic constellation underlying Alzheimer’s disease (AD) is important. Doing so allows us to identify biological pathways underlying AD, point towards novel drug targets and use the variants for individualised risk predictions in disease modifying or prevention trials. In the present work we report on the largest genome-wide association study (GWAS) for AD risk to date and show the combined utility of proven AD loci for precision medicine using polygenic risk scores (PRS).METHODS Three sets of summary statistics were included in our meta-GWAS of AD: an Spanish case-control study (GR@ACE/DEGESCO study, n = 12,386), the case-control study of International Genomics of Alzheimer project (IGAP, n = 82,771) and the UK Biobank (UKB) AD-by-proxy case-control study (n=314,278). Using these resources, we performed a fixed-effects inverse-variance-weighted meta-analysis. Detected loci were confirmed in a replication study of 19,089 AD cases and 39,101 controls from 16 European-ancestry cohorts not previously used. We constructed a weighted PRS based on the 39 AD variants. PRS were generated by multiplying the genotype dosage of each risk allele for each variant by its respective weight, and then summing across all variants. We first validated it for AD in independent data (assessing effects of sub-threshold signal, diagnostic certainty, age at onset and sex) and tested its effect on risk (odds for disease) and age at onset in the GR@ACE/DEGESCO study.FINDINGS Using our meta-GWAS approach and follow-up analysis, we identified novel genome-wide significant associations of six genetic variants with AD risk (rs72835061-CHRNE, rs2154481-APP, rs876461-PRKD3/NDUFAF7, rs3935877-PLCG2 and two missense variants: rs34173062/rs34674752 in SHARPIN gene) and confirmed a stop codon mutation in the IL34 gene increasing the risk of AD (IL34-Tyr213Ter), and two other variants in PLCG2 and HS3ST1 regions. This brings the total number of genetic variants associated with AD to 39 (excluding APOE). The PRS based on these variants was associated with AD in an independent clinical AD-case control dataset (OR=1.30, per 1-SD increase in the PRS, 95%CI 1.18-1.44, p = 1.1×10−7), a similar effect to that in the GR@ACE/DEGESCO (OR=1.27, 95%CI 1.23-1.32, p = 7.4×10−39). We then explored the combined effects of these 39 variants in a PRS for AD risk and age-at-onset stratification in GR@ACE/DEGESCO. Excluding APOE, we observed a gradual risk increase over the 2% tiles; when comparing the extremes, those with the 2% highest risk had a 2.98-fold (95% CI 2.12–4.18, p = 3.2×10−10) increased risk compared to those with the 2% lowest risk (p = 5.9×10−10). Using the PRS we identified APOE ε33 carriers with a similar risk as APOE ε4 heterozygotes carriers, as well as APOE ε4 heterozygote carriers with a similar risk as APOE ε4 homozygote. Considering age at onset; there was a 9-year difference between median onset of AD the lowest risk group and the highest risk group (82 vs 73 years; p = 1.6×10−6); a 4-year median onset difference (81 vs 77 years; p = 6.9×10−5) within APOE ε4 heterozygotes and a 5.5-year median onset difference (78.5 vs 73 years; p = 4.6×10−5) within APOE ε4 carriers.INTERPRETATION We identified six novel genetic variants associated with AD-risk, among which one common APP variant. A PRS of all genetic loci reported to date could be a robust tool to predict the risk and age at onset of AD, beyond APOE alone. These properties make PRS instrumental in selecting individuals at risk in order to apply preventative strategies and might have potential use in diagnostic work-up.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Genome Research @ Fundació ACE project (GR@ACE) is supported by Grifols SA, Fundación bancaria ‘La Caixa’, Fundació ACE, and CIBERNED. A.R. and M.B. receive support from the European Union/EFPIA Innovative Medicines Initiative Joint undertaking ADAPTED and MOPEAD projects (grant numbers 115975 and 115985, respectively). M.B. and A.R. are also supported by national grants PI13/02434, PI16/01861, PI17/01474 and PI19/01240. Acción Estratégica en Salud is integrated into the Spanish National R + D + I Plan and funded by ISCIII (Instituto de Salud Carlos III)–Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER–’Una manera de hacer Europ’). Amsterdam dementia Cohort (ADC): Research of the Alzheimer center Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. The Alzheimer Center Amsterdam is supported by Stichting Alzheimer Nederland and Stichting VUmc fonds. The clinical database structure was developed with funding from Stichting Dioraphte. Genotyping of the Dutch case-control samples was performed in the context of EADB (European Alzheimer DNA biobank) funded by the JPco-fuND FP-829-029 (ZonMW projectnumber 733051061). 100-Plus study: This work was supported by Stichting Alzheimer Nederland (WE09.2014-03), Stichting Diorapthe, horstingstuit foundation, Memorabel (ZonMW projectnumber 733050814) and Stichting VUmc Fonds. Genotyping of the 100-Plus Study was performed in the context of EADB (European Alzheimer DNA biobank) funded by the JPco-fuND FP-829-029 (ZonMW projectnumber 733051061). Longitudinal Aging Study Amsterdam (LASA) is largely supported by a grant from the Netherlands Ministry of Health, Welfare and Sports, Directorate of Long-Term Care.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot Applicable